Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 28.3%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 7,700 shares, a growth of 28.3% from the February 28th total of 6,000 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average daily trading volume, of 12,600 shares, the short-interest ratio is presently 0.6 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Armata Pharmaceuticals in a research report on Thursday, December 19th.

Armata Pharmaceuticals Trading Down 9.7 %

NYSEAMERICAN ARMP opened at $1.30 on Thursday. Armata Pharmaceuticals has a one year low of $1.30 and a one year high of $3.85. The stock has a market cap of $47.03 million, a PE ratio of -0.79 and a beta of 0.87.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.